Metraipolis › archive › dc_abfaeaa0fe3b

A Real-World Study of Tafasitamab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States — Europe PMC PMID:42824791

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42824791
DOI
10.1002/jha2.70256
License (as archived)
solo-consultazione
Archived
2026-11-03T20:45:34.363Z
SHA-256 of the archived text
4acf5298be9de5a7a43e773b09b39dde97e541db71d7978a4229c07bb5e9382f
Stable URL of this page
https://metraipolis.com/documento/dc_abfaeaa0fe3b

How to cite

A Real-World Study of Tafasitamab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States — Europe PMC PMID:42824791 — Europe PMC (en), https://europepmc.org/article/MED/42824791 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_abfaeaa0fe3b (Metraipolis archive dc_abfaeaa0fe3b, sha256 4acf5298be9de5a7a43e773b09b39dde97e541db71d7978a4229c07bb5e9382f)
BibTeX
@misc{dcabfaeaa0fe3b,
  title = {A Real-World Study of Tafasitamab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States — Europe PMC PMID:42824791},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42824791},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_abfaeaa0fe3b; sha256 4acf5298be9de5a7a43e773b09b39dde97e541db71d7978a4229c07bb5e9382f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42824791. Agents can read the archived copy with the MCP tool read_document.